Market Research Report
Biosimulation Market - Size, Share, trends, and Forecast to 2026
|Published by||Coherent Market Insights||Product code||678012|
|Published||Content info||159 Pages
Delivery time: 2-3 business days
|Biosimulation Market - Size, Share, trends, and Forecast to 2026|
|Published: July 30, 2018||Content info: 159 Pages||
Biosimulation plays important role in research and development process. Biosimulation is widely used in consumer personalized medicine, owing to increasing demand for personalized medicine in offering tailored solutions for various treatment areas such as drug discovery, oncology, cardiology, infectious disease, and psychiatry. Predictive biosimulation offers effective platform to use biological data and mathematical modeling to create a virtual version of patient to test simulated treatments.
Moreover, continuous research is being conducted to create a low-priced or open source version of predictive biosimulation platforms for self-tracking and modeling using patient’s data and to speed up the adoption by software development communities to generate future health scenarios using patient’s medication data.
Market players are engaged in developing novel biosimulation platform, in order to offer tailored solution in each therapeutic area. This is expected to aid in growth of the market. For instance, in October 2013, Rhenovia Pharma: a biotechnology firm specialized in biosimulation has developed the first simulator for biological mechanism of epilepsy. Moreover, development of new simulator opens new possibilities for research in epilepsy treatment. Rhenovia’ new simulator replicates the basic biological mechanisms of signal transmission between brain cells and simulates its defects leading to epileptic patterns, thereby leading to prevent epileptic seizures.
Furthermore, growing support from heathcare regulatory organizations in the adoption of biosimulation based software and services will, augment future growth of biosimulation market. Current FDA and EMA guidelines recommends the use of biosimulation in pediatric drug development studies, thereby minimizing the impact on children that must enroll in clinical trials. For instance, in Novembr 2017, Certara stated that U.S. Food and Drug Administration (FDA), expanded its use of Certara’s PBPK Simcyp Population-based Simulator and its Pediatric and Cardiac Safety Simulators. In addition, under the new agreement, FDA has tripled its number of licenses, equipping its Modeling and Simulation (M&S) review team with almost 60 PBPK licenses.
This report provides in-depth analysis of biosimulation market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global biosimulation market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies and future plans
Key companies covered as a part of this study include Certara, L.P., Simulations Plus, Inc., Dassault Systèmes (Accelrys), Genedata AG, LeadScope, Inc., Compugen Inc., Schrödinger, LLC, In Silico Biosciences, Inc., Advanced Chemistry Development, Inc., Chemical Computing Group ULC, Physiomics PLC, and Pharmaceutical Product Development, LLC (Evidera)
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global biosimulation market report caters to various stakeholders in this industry including investors, suppliers, biosimulation software and services provider, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the biosimulation market.